What's Happening?
Beckman Coulter Diagnostics has received CE mark approval for its Access MeMed BV assay, a high-throughput test that differentiates between bacterial and viral infections in approximately 20 minutes. This assay, validated for use with Beckman Coulter's
DxI 9000 and Access 2 immunoassay analyzers, aims to enhance clinical decision-making and reduce unnecessary antibiotic use. The test leverages existing laboratory infrastructure, offering a scalable solution to improve antimicrobial stewardship. Real-world studies have shown that the test supports or changes clinical decision-making in a significant percentage of cases, potentially reducing healthcare costs and unnecessary hospital admissions.
Why It's Important?
The introduction of the Access MeMed BV assay represents a significant advancement in diagnostic testing, offering rapid and reliable differentiation between bacterial and viral infections. This capability is crucial for guiding appropriate treatment decisions, particularly in reducing the misuse of antibiotics, which is a major public health concern. By enabling faster and more accurate diagnoses, the assay can help healthcare systems reduce costs associated with unnecessary treatments and hospitalizations, ultimately improving patient outcomes and supporting global efforts in antimicrobial stewardship.
